期刊
NATURE CHEMICAL BIOLOGY
卷 11, 期 6, 页码 401-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio.1797
关键词
-
资金
- Welch Foundation [I-1414, I-1689]
- US National Cancer Institute [CA071443, CA176284, CA149833]
- Cancer Prevention and Research Institute of Texas [RP120718, RP110708]
- Komen
- US National Institutes of Health [2T32GM008203]
- Cancer Interventions and Discoveries Program [RP101496]
Modern cancer treatment employs many effective chemotherapeutic agents originally discovered from natural sources. The cyclic depsipeptide didemnin B has demonstrated impressive anticancer activity in preclinical models. Clinical use has been approved but is limited by sparse patient responses combined with toxicity risk and an unclear mechanism of action. From a broad-scale effort to match antineoplastic natural products to their cellular activities, we found that didemnin B selectively induces rapid and wholesale apoptosis through dual inhibition of PPT1 and EEF1A1. Furthermore, empirical discovery of a small panel of exceptional responders to didemnin B allowed the generation of a regularized regression model to extract a sparse-feature genetic biomarker capable of predicting sensitivity to didemnin B. This may facilitate patient selection in a fashion that could enhance and expand the therapeutic application of didemnin B against neoplastic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据